ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study

Stock News12-16

ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million.

On December 15, ASCLETIS-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the U.S. for ASC50. The study, a single ascending dose (SAD) trial in healthy volunteers, evaluated the safety, tolerability, pharmacokinetics, and interleukin-17A (IL-17A) target engagement in peripheral circulation.

A total of 46 healthy participants received doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50 or a matching placebo. The study aimed to assess safety, tolerability, pharmacokinetics, and target engagement.

ASC50 is an orally administered small-molecule IL-17 inhibitor independently developed by ASCLETIS. IL-17 has been biologically validated in multiple autoimmune and inflammatory diseases, including psoriasis, and holds established commercial value. ASC50 is a new chemical entity (NCE) with U.S. and global compound patent protection extending until 2043 (excluding potential patent extensions).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133417637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133417637","market":"sh","top_or_hot":-1,"title":"ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study","media":"Stock News","content":"<p>ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million.</p>\n<p>On December 15, ASCLETIS-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the U.S. for ASC50. The study, a single ascending dose (SAD) trial in healthy volunteers, evaluated the safety, tolerability, pharmacokinetics, and interleukin-17A (IL-17A) target engagement in peripheral circulation.</p>\n<p>A total of 46 healthy participants received doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50 or a matching placebo. The study aimed to assess safety, tolerability, pharmacokinetics, and target engagement.</p>\n<p>ASC50 is an orally administered small-molecule IL-17 inhibitor independently developed by ASCLETIS. IL-17 has been biologically validated in multiple autoimmune and inflammatory diseases, including psoriasis, and holds established commercial value. ASC50 is a new chemical entity (NCE) with U.S. and global compound patent protection extending until 2043 (excluding potential patent extensions).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-16 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million.</p>\n<p>On December 15, ASCLETIS-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the U.S. for ASC50. The study, a single ascending dose (SAD) trial in healthy volunteers, evaluated the safety, tolerability, pharmacokinetics, and interleukin-17A (IL-17A) target engagement in peripheral circulation.</p>\n<p>A total of 46 healthy participants received doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50 or a matching placebo. The study aimed to assess safety, tolerability, pharmacokinetics, and target engagement.</p>\n<p>ASC50 is an orally administered small-molecule IL-17 inhibitor independently developed by ASCLETIS. IL-17 has been biologically validated in multiple autoimmune and inflammatory diseases, including psoriasis, and holds established commercial value. ASC50 is a new chemical entity (NCE) with U.S. and global compound patent protection extending until 2043 (excluding potential patent extensions).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1133417637","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133417637","pubTimestamp":1765850774,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million. On December 15, ASCLETIS-B announced positive topline results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B","BK1515":"抗疫概念","01477":"欧康维视生物-B","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"歌礼-B(01672)反弹近3%，IL-17抑制剂ASC50在美国I期研究取得积极顶线结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million.\nOn December 15, ASCLETIS-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the U.S. for ASC50. The study, a single ascending dose (SAD) trial in healthy volunteers, evaluated the safety, tolerability, pharmacokinetics, and interleukin-17A (IL-17A) target engagement in peripheral circulation.\nA total of 46 healthy participants received doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50 or a matching placebo. The study aimed to assess safety, tolerability, pharmacokinetics, and target engagement.\nASC50 is an orally administered small-molecule IL-17 inhibitor independently developed by ASCLETIS. IL-17 has been biologically validated in multiple autoimmune and inflammatory diseases, including psoriasis, and holds established commercial value. ASC50 is a new chemical entity (NCE) with U.S. and global compound patent protection extending until 2043 (excluding potential patent extensions).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133417637","isCrawlerRequest":true}